Sign Up | Log In | What is SocialPicks?

CELSCISci Corp (CVM) Trade Now » Rate CVM - Discuss CVM - Add to Watch List

Sector: Healthcare > Industry: Biotechnology & Drugs

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

86.5%

Top:

0.0%

Rate CVM:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

CVM Analysis & Videos »

... View All >

CVM: Bull or Bear?

BioMed Momentum Index: Pause that Refreshes or More Pain to Come? CVM

73%

-15.74%
in 38 days

Below is a 10-stock BioMed Momentum Index that I have created along with related financial data from Google Finance as of 10/28/09, including the stock price, 52-week change, average daily trading volume, and market cap. I have screened for small and micro-cap stocks with market caps of approximately $500 million (M) or lower with stock price increases of at least 50% in the past year and average trading volume of at least 1M shares per day.

<font> http://www.proactivenewsroom.com/Blog/bid/29544/BioMed-Moment... </font>

<> 1.) Antigenics (NASDAQ: AGEN) ($...

Continue reading »

By Mike Havrilla (+1.04% risk: conservative) 10/29/09

Comment

Fundamental Analysis CVM

N/A

-5.30%
in 80 days

<> <>

CVM

Our research and development programs focus on exploiting the power of immunotherapy to develop new therapies that address the unmet medical needs of patients with cancer and infectious diseases. To that end, CEL-SCI is currently preparing to initiate a Global Phase III clinical trial of Multikine ® in patients with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity, a debilitating life-threatening disease, for which the overall five year survival rate has not materially improved over several decades.

<> Multikine ® , CEL-SCI’s flagship canc<><><><><><><><><><><><>...

Continue reading »

By Olof Thomas (-3.07% risk: conservative) 09/17/09

Comment

... View All >

People Bullish on CVM

mbmalone

Analyst

N/A

about 1 mo ago

donkimchi

Analyst

N/A

2 mos ago

mzalowitz

Analyst

N/A

2 mos ago

ireneak

Analyst

N/A

2 mos ago

carrier5

Analyst

N/A

2 mos ago

People Bearish on CVM

Mike Havrilla

Principal

73%

about 1 mo ago

... View All >

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.44%	381
2	Gerald Greene	18.14	+71.24%	211
3	stockmarketfunding.com	17.66	+25.60%	55
4	akiralegrand	13.47	+14.32%	62
5	anup2104	12.13	+74.22%	40

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
F	Ford Motor Company
ETFC	E*Trade Financial Corp
AIG	American International Group Inc.
NVDA	NVIDIA Corp
BIDU	Baiducom Inc ADS
C	Citigroup Inc

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

DNDN		Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: D... by Mike Havrilla
CLDA		BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: ... by Mike Havrilla
PARD		Biotech Stocks - Beware of The Covered Call Trap by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev

... more »

StreetInsider.com on CVM

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

Form 4 CEL SCI CORP For: Nov 18 Filed by: DE CLARA MAXIMILIAN

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine

Is Amendment of Previously Filed Paperwork a Sign That CEL-SCI is Expecting Something Big?

Form S-3/A CEL SCI CORP

Discussion Wall

+ Add

amritadas (+0.00%)

A FREE report on the approval of a new Gout Drug - An upcoming treatment by a small cap company for Gout to face FDA decision on approval shortly. Gout has traditionally been a difficult disease to tre

+	0 replies

amritadas (+0.00%)

Free report on upcoming FDA panel decision of Corvu.. - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...

+	0 replies

... more »

More Resources

About CELSCISci Corp - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.